Jade Biosciences, Inc. (JBIO) stock
JBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
$15.49+0.09 (+0.58%)
Close on Nov 18, 2026Market cap $985.12MP/E –Yield –
Jade Biosciences operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Jade Biosciences's operating income for the twelve months ending Sep 30, 2026 was -$176.98M. For fiscal 2025 it was -$113.54M. The highest annual figure on record is -$8.89M in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$113.54M | – |
| FY2024 | Dec 31, 2024 | -$74.60M | – |
| FY2023 | Dec 31, 2023 | -$81.41M | – |
| FY2022 | Dec 31, 2022 | -$53.24M | – |
| FY2021 | Dec 31, 2021 | -$23.02M | – |
| FY2020 | Dec 31, 2020 | -$8.89M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$39.64M | – |
| Q2 FY2026 | Jun 30, 2026 | -$58.92M | – |
| Q1 FY2026 | Mar 31, 2026 | -$43.45M | – |
| Q4 FY2025 | Dec 31, 2025 | -$34.98M | – |
| Q3 FY2025 | Sep 30, 2025 | -$27.40M | – |
| Q2 FY2025 | Jun 30, 2025 | -$27.78M | – |
| Q1 FY2025 | Mar 31, 2025 | -$23.38M | – |
| Q4 FY2024 | Dec 31, 2024 | -$6.40M | – |
| Q3 FY2024 | Sep 30, 2024 | -$14.97M | – |
| Q2 FY2024 | Jun 30, 2024 | -$26.17M | – |
| Q1 FY2024 | Mar 31, 2024 | -$24.62M | – |
| Q4 FY2023 | Dec 31, 2023 | -$22.07M | – |
| Q3 FY2023 | Sep 30, 2023 | -$21.37M | – |
| Q2 FY2023 | Jun 30, 2023 | -$20.34M | – |
| Q1 FY2023 | Mar 31, 2023 | -$17.64M | – |
| Q4 FY2022 | Dec 31, 2022 | -$15.85M | – |
| Q3 FY2022 | Sep 30, 2022 | -$14.15M | – |
| Q2 FY2022 | Jun 30, 2022 | -$12.22M | – |
| Q1 FY2022 | Mar 31, 2022 | -$11.02M | – |
| Q4 FY2021 | Dec 31, 2021 | -$8.27M | – |
| Q3 FY2021 | Sep 30, 2021 | -$6.20M | – |
| Q2 FY2021 | Jun 30, 2021 | -$5.77M | – |
| Q1 FY2021 | Mar 31, 2021 | -$2.78M | – |
| Q4 FY2020 | Dec 31, 2020 | -$3.66M | – |
| Q3 FY2020 | Sep 30, 2020 | -$2.24M | – |
| Q2 FY2020 | Jun 30, 2020 | -$1.63M | – |
See a number that looks wrong?